View gallery.It’s been a rough couple of days for biotech stocks.To start, Gilead Sciences, Inc. (NASDAQ: GILD) has dropped from a high of almost $110 per share on Friday to a low of $86 on Tuesday.Many other big-name biotechs, such as Amgen, Inc. (NASDAQ: AMGN), Biogen Idec Inc (NASDAQ: BIIB) and Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have fallen with […]
View gallery.A recent report by Morgan Stanley predicts a greater than 40 percent growth in the Hepatitis C (HCV) market in 2015. Projections indicate that the HCV market could be worth $15 billion in upcoming years, with two-thirds of treatment occurring in the United States.
HCV Forerunners Gilead And AbbVie
Morgan Stanley projects that Gilead Sciences, Inc.’s (NASDAQ: GILD) Harvoni and Sovaldi […]
The stock market has been racing higher at nearly unprecedented levels in recent years. Even so, the healthcare sector in general, and biopharma stocks in particular, have still managed to crush the broader markets over the last few years. Since 2012, for instance, the iShares Nasdaq Biotech Index has more than tripled the returns of the closely watched S&P 500:Perhaps […]
Biotechnology stocks have been among the market’s top performers this year, with the iShares Nasdaq Biotechnology ETF’s 36% gain handily outpacing the S&P 500 ‘s 14% return. That heady return, however, comes with one potential drawback: It might be tough to figure out which biotech stocks will continue climbing next year. With that in mind, here are three large-cap biotech […]
Michael A. RobinsonToday I want to reintroduce you to a biotech stock that Wall Street has been pricing as though it were dead money.This biotech company recently filed a stellar earnings report. But those earnings were slightly off analyst expectations, and the share price dipped – making this is yet another stock that sells off after a slight miss, a […]
Geron Corporation (GERN – Analyst Report) was in the spotlight last week with the company striking a collaboration deal with Johnson & Johnson for its sole pipeline candidate, imetelstat. Meanwhile, companies like Gilead (GILD – Analyst Report) and Regeneron (REGN – Analyst Report) remained in the news thanks to regulatory updates.Recap of the Week’s Most Important Stories1. Geron, which had […]
The number of patients with this chronic liver disease, which can lead to permanent liver scarring, eclipses that of hepatitis C in the U.S., RBC’s Yee said. While a significant number aren’t diagnosed, “we believe, based on survey work, that there are hundreds of thousands of patients with diagnosed NASH,” and that the global market for NASH drugs may reach […]
Benchmarks ended lower on Wednesday following disappointing corporate results and economic data. AT&T, Amgen and Biogen posted disappointing corporate results. Boeing and Gilead’s better-than-expected quarterly earnings failed to restrict the day’s losses. Decline in new home sales data also added to the bearish sentiment.For a look at the issues currently facing the markets, make sure to read today’s Ahead […]
